Prostate cancer is the most frequent male malignancy diagnosed in western countries and the second leading cause of cancer-related deaths. The growth and function of the prostate gland depends on androgens. Owing to the importance of androgens in prostate development, genes involved in androgen biosynthesis and metabolism have been extensively studied. In this review, we address recent progress toward the use of inherited and acquired genetic variants to predict susceptibility and clinical outcomes of prostate cancer patients. Many of these genetic variants involve several genes related to the biosynthesis and metabolism of androgens, such as steroid-5-alpha-reductase, alpha polypeptide 2 (SRD5A2), cytochrome P450 (CYP)19A1, CYP17A1, hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 (HSD3B2) and androgen receptor (AR). With increasing knowledge, it may be possible to distinguish indolent from aggressive prostate tumors by molecular fingerprinting. Furthermore, with the emergence of new investigative tools, such as microarray platforms and comparative genomic hybridization (CGH) array, a variety of new genomic biomarkers will be available in the future to provide accurate prognostic and monitoring solutions for individualized patient care.

D'Amico, F., Biancolella, M., Margiotti, K., Reichardt, J., & Novelli, G. (2007). Genomic biomarkers androgen pathway and prostate cancer. PHARMACOGENOMICS, 8(6), 645-661 [10.2217/14622416.8.6.645].

Genomic biomarkers androgen pathway and prostate cancer

D'AMICO, FRANCA;BIANCOLELLA, MICHELA;MARGIOTTI, KATIA;NOVELLI, GIUSEPPE
2007

Abstract

Prostate cancer is the most frequent male malignancy diagnosed in western countries and the second leading cause of cancer-related deaths. The growth and function of the prostate gland depends on androgens. Owing to the importance of androgens in prostate development, genes involved in androgen biosynthesis and metabolism have been extensively studied. In this review, we address recent progress toward the use of inherited and acquired genetic variants to predict susceptibility and clinical outcomes of prostate cancer patients. Many of these genetic variants involve several genes related to the biosynthesis and metabolism of androgens, such as steroid-5-alpha-reductase, alpha polypeptide 2 (SRD5A2), cytochrome P450 (CYP)19A1, CYP17A1, hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 (HSD3B2) and androgen receptor (AR). With increasing knowledge, it may be possible to distinguish indolent from aggressive prostate tumors by molecular fingerprinting. Furthermore, with the emergence of new investigative tools, such as microarray platforms and comparative genomic hybridization (CGH) array, a variety of new genomic biomarkers will be available in the future to provide accurate prognostic and monitoring solutions for individualized patient care.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/03 - Genetica Medica
English
Con Impact Factor ISI
Androgens; Genetic Markers; Humans; Male; Polymorphism, Genetic; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction
D'Amico, F., Biancolella, M., Margiotti, K., Reichardt, J., & Novelli, G. (2007). Genomic biomarkers androgen pathway and prostate cancer. PHARMACOGENOMICS, 8(6), 645-661 [10.2217/14622416.8.6.645].
D'Amico, F; Biancolella, M; Margiotti, K; Reichardt, J; Novelli, G
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
D'Amico F,et al. 2007.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 364.3 kB
Formato Adobe PDF
364.3 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/169268
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact